期刊
NATURE BIOTECHNOLOGY
卷 32, 期 6, 页码 551-553出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.2884
关键词
-
资金
- National Cancer Institute [2-PO1-CA42063, P30-CA14051]
- National Institutes of Health (NIH) [R01-CA133404]
- Howard Hughes Investigator
- NIH Centers for Cancer Nanotechnology Excellence and the Harvard-MIT Center of Cancer Nanotechnology Excellence [5-U51-CA151884-04]
- Damon Runyon Fellow [DRG2117- 12]
- [1K99CA169512]
We demonstrate CRISPR-Cas9-mediated correction of a Fah mutation in hepatocytes in a mouse model of the human disease hereditary tyrosinemia. Delivery of components of the CRISPR-Cas9 system by hydrodynamic injection resulted in initial expression of the wild-type Fah protein in similar to 1/250 liver cells. Expansion of Fah-positive hepatocytes rescued the body weight loss phenotype. Our study indicates that CRISPR-Cas9-mediated genome editing is possible in adult animals and has potential for correction of human genetic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据